CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$300.02−0.13 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $14.41B
- P/E (TTM)
- –
- Dividend yield
- –
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DSA | $606.51M | $596.92M | $591.57M | $600.69M | $618.03M | $592.61M | $603.35M | $615.06M | $627.42M | $605.45M | $625.79M | $664.03M | 60.4% | -1.9% |
| RMS | $209.48M | $208.37M | $206.26M | $213.47M | $213.27M | $213.07M | $204.26M | $197.82M | $206.39M | $220.91M | $195.78M | $186.85M | 20.9% | -1.8% |
| Manufacturing | $188.10M | $190.54M | $196.40M | $190.69M | $200.84M | $178.49M | $194.94M | $196.88M | $192.31M | $185.20M | $191.91M | $175.75M | 18.7% | -6.3% |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Segment operating income | $226.28M | $200.49M | -$212.36M | $197.63M | $170.63M | $128.94M | -$105.92M | $194.17M | $205.55M | $191.67M | – | – | +32.6% |
| DSA | $124.40M | $103.88M | $84.67M | $123.15M | $122.78M | $93.95M | $62.86M | $126.44M | $138.38M | $114.84M | $126.29M | $146.82M | +1.3% |
| Manufacturing | $65.61M | $46.84M | -$227.65M | $39.93M | $12.06M | -$8.62M | -$182.55M | $40.19M | $37.23M | $33.68M | $35.55M | $26.28M | +444.0% |
| RMS | $36.28M | $49.77M | -$69.38M | $34.55M | $35.79M | $43.61M | $13.77M | $27.54M | $29.95M | $43.15M | $37.01M | $28.33M | +1.4% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of services provided (excluding amortization of intangible assets) | $808.29M | $798.15M | $803.30M | $808.04M | $840.84M | $797.92M | $811.91M | $832.46M | $842.90M | $816.86M | $838.00M | $869.76M | 80.5% | -3.9% |
| Product | $195.79M | $197.68M | $190.93M | $196.81M | $191.30M | $186.25M | $190.64M | $177.30M | $183.22M | $194.70M | $175.47M | $156.86M | 19.5% | +2.3% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $539.86M | $543.81M | $517.35M | $537.61M | $549.86M | $536.96M | $546.96M | $559.28M | $571.43M | $562.32M | $544.95M | $590.32M | 53.8% | -1.8% |
| Europe | $263.07M | $277.58M | $279.90M | $277.69M | $281.86M | $263.25M | $263.33M | $267.12M | $271.38M | $276.32M | $271.47M | $264.79M | 26.2% | -6.7% |
| Canada | $127.51M | $109.57M | $123.28M | $116.81M | $135.59M | $125.35M | $119.36M | $127.09M | $125.24M | $110.40M | $130.03M | $129.02M | 12.7% | -6.0% |
| Asia Pacific | $60.52M | $55.48M | $56.91M | $51.66M | $54.50M | $41.94M | $55.78M | $45.01M | $50.39M | $45.77M | $57.92M | $40.23M | 6.0% | +11.0% |
| Other | $13.12M | $9.40M | $16.79M | $21.08M | $10.33M | $16.67M | $17.12M | $11.27M | $7.68M | $16.75M | $9.10M | $2.26M | 1.3% | +27.0% |
From the segment and revenue-disaggregation notes of Charles River Laboratories International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.